Lesson
See the Dependence, Not Only the Product
Nicotine use becomes durable through receptor activation, rapid reward, cue learning, tolerance, and withdrawal. The first task is to reconstruct the complete exposure and understand what keeps it in place.
- Nicotinic receptors
- Reward and withdrawal
- All nicotine products
- Pack-years
- Dependence assessment
Rapid nicotine delivery stimulates reward pathways.
Repeated exposure changes the response to falling nicotine levels.
Routines and stress begin to predict and trigger another dose.
Map the biologic loop
Nicotine activates neuronal nicotinic acetylcholine receptors and increases dopamine signaling in reward pathways. Repeated exposure changes receptor systems and connects nicotine with people, places, stress, meals, and routines. Falling nicotine concentrations then produce withdrawal and reinforce another dose.
Reconstruct every source
Document cigarettes, cigars, pipes, hookah, smokeless tobacco, heated products, e-cigarettes, pouches, and therapeutic nicotine. Record amount, strength when known, timing, dual use, first use after waking, overnight use, and the situations that prompt use. A low cigarette count can coexist with high total nicotine exposure.
Use pack-years correctly
Pack-years equal packs smoked per day multiplied by years smoked. A pack usually represents 20 cigarettes. This estimate helps characterize cumulative cigarette exposure, but it does not measure current withdrawal, set a nicotine dose, or replace age-appropriate cancer screening criteria.
Treat dependence as chronic
Repeated attempts are expected in a chronic relapsing condition. Review what helped, what was intolerable, when return to use occurred, and whether medication was used correctly or long enough. The history is design information for the next plan, not evidence of personal failure.
Quick check
Lesson
Turn a Quit Attempt Into a Treatment Plan
Advice matters, but a plan changes behavior. A complete approach links motivation, medication, cue management, support, follow-up, and a way to recover from lapses without shame.
- Five As
- Behavioral counseling
- Quitline
- Trigger planning
- Lapse recovery
Identify routines, stressors, support, and the desired change.
Control withdrawal while replacing learned responses.
Review response early and use a lapse to strengthen the plan.
Begin with respect and clarity
Ask about current use without judgment and advise cessation in clear, personalized language. Explore what the patient wants to change, confidence, concerns, and prior experiences. Readiness is a point in the conversation, not a gate that determines whether help is offered.
Design around real cues
Identify high-risk routines such as waking, commuting, meals, alcohol, social settings, stress, boredom, and contact with other users. Pair each cue with a specific response, including medication timing, movement, breathing, a substitute behavior, social support, or leaving the setting.
Connect behavioral support
Counseling and medication together provide the strongest quit opportunity for many adults. Support can be individual, group, telephone, text, or digital. In the United States, 1-800-QUIT-NOW provides free confidential coaching and local connections.
Plan for a lapse
A single use should trigger curiosity and rapid recovery rather than an all-or-nothing verdict. Identify the trigger, remove remaining products, resume the treatment plan, and decide what needs to change. Repeated regular use warrants a new assessment, not abandonment of care.
Quick check
Lesson
Build Baseline Control and Craving Rescue
Nicotine replacement reduces withdrawal without exposing the patient to the combustion products that drive much of smoking-related disease. Formulation and technique determine whether replacement is adequate and usable.
- NRT safety
- Long-acting control
- Short-acting rescue
- Combination NRT
- Nicotine toxicity
Reduces baseline withdrawal across the day.
Gum or lozenge addresses a breakthrough craving.
Symptoms, all products, and correct technique guide adjustment.
Separate nicotine from smoke
Nicotine sustains dependence and has physiologic effects, but therapeutic nicotine does not deliver carbon monoxide and the many toxic combustion products in cigarette smoke. For most adults, approved cessation medicines are much safer than continued smoking.
Use two time scales
A patch provides slow baseline delivery. Gum, lozenge, inhaler, or nasal spray can address breakthrough cravings with different speed, technique, and local effects. Combination NRT commonly pairs one long-acting product with one short-acting product rather than simply doubling products.
Individualize precautions
Review recent unstable cardiovascular events, pregnancy or lactation, age, active nicotine use, skin, dental, nasal, or airway conditions, and product-specific labeling. Stable cardiovascular disease should not be treated as an automatic exclusion from all NRT.
Recognize excess exposure
Nausea, vomiting, dizziness, sweating, salivation, headache, weakness, and palpitations can reflect too much nicotine. Count therapeutic and consumer sources together. Used products retain nicotine and must be secured from children and pets.
Quick check
Lesson
Use the Patch as a Reliable Baseline
The patch is simple only when the starting strength, wear schedule, application, sleep effects, skin response, and disposal are understood.
- Starting strength
- Application
- Sleep effects
- Skin reactions
- Safe disposal
Rotate sites and avoid direct heat or irritated skin.
Overnight wear is adjusted to benefit and tolerability.
Fold used patches and protect children and pets.
Choose from current exposure
Common OTC products use current cigarettes per day to select a starting regimen, but the full dependence pattern still matters. Verify the exact brand schedule because step strengths and durations vary. Reassess early if withdrawal remains strong or nicotine-related symptoms emerge.
Apply to intact skin
Place one patch on clean, dry, hairless, intact skin and rotate sites. Wash hands after application. Do not apply over irritated skin or expose the patch to direct heat, which can alter delivery. Cutting is not a routine dosing strategy unless the specific product supports it.
Balance sleep and morning cravings
Twenty-four-hour use can improve early morning control but may contribute to vivid dreams or insomnia. If sleep effects are troublesome and morning craving is manageable, product directions may allow bedtime removal and a fresh patch in the morning.
Dispose as active medicine
Fold used patches with adhesive sides together and use the disposal pouch when provided. Secure them from children and pets. A used patch still contains enough nicotine to cause poisoning.
Quick check
Lesson
Make Gum and Lozenges Work at the Buccal Surface
Gum and lozenges fail when treated like ordinary candy. Buccal absorption depends on strength selection, technique, contact time, and separation from food and acidic drinks.
- Chew and park
- Lozenge dissolution
- Time to first cigarette
- Food and beverages
- Dental fit
Create controlled contact with the oral mucosa.
Limit swallowed nicotine and gastrointestinal effects.
Avoid acidic beverages around the dose.
Chew and park
Chew nicotine gum slowly until tingling, then park it between the cheek and gum. Repeat the cycle until the dose is exhausted. Rapid continuous chewing increases swallowed nicotine and can produce hiccups, nausea, jaw discomfort, and dyspepsia.
Let the lozenge dissolve
Move the lozenge occasionally from one side of the mouth to the other and allow it to dissolve slowly. Do not chew or swallow it. Review the product schedule and maximum daily use rather than relying on craving alone.
Protect buccal absorption
Avoid food and drinks for about 15 minutes before and during use according to product directions. Acidic beverages such as coffee, soda, and juice can interfere with absorption. Rescue NRT works best when used before or at the beginning of a predictable craving.
Select for the mouth and routine
Dentures, temporomandibular pain, dental work, mouth irritation, dexterity, and the ability to follow technique can determine whether gum or lozenge is practical. The best formulation is one the patient can use correctly and consistently.
Quick check
Lesson
Choose Speed, Ritual, and Tolerability
The prescription oral inhaler and nasal spray offer different forms of rapid support. Their value depends on product-specific technique, local anatomy, irritation, access, and misuse risk.
- Oral inhaler
- Buccal absorption
- Nasal spray
- Local irritation
- Product selection
Buccal absorption supports ritual replacement.
One spray per nostril treats intense cravings.
Airway, nasal disease, irritation, and preference change the choice.
Use the inhaler as designed
The nicotine inhaler uses frequent shallow puffing, with most nicotine absorbed through the mouth and throat rather than deeply in the lungs. Cold temperature can reduce delivery. Review cartridge use, cleaning, storage, and secure disposal.
Prepare for local effects
Mouth and throat irritation and cough are common early with the inhaler. Anticipatory counseling and correct technique can improve persistence. Severe symptoms or inability to use the product require reassessment rather than automatic endurance.
Administer nasal spray correctly
Use one spray in each nostril per dose according to the prescription. Do not sniff, swallow, or inhale during administration. Nasal and throat irritation, watery eyes, sneezing, and cough are common early effects.
Match the person and product
Consider asthma or bronchospasm, chronic nasal disease, hand-to-mouth preferences, craving speed, prior misuse, dexterity, and cost. Faster delivery is not automatically the best choice for every patient.
Quick check
Lesson
Use Partial Agonism to Reduce Withdrawal and Reward
Varenicline combines strong adult efficacy with flexible initiation, renal dose boundaries, and a safety conversation that must reflect current labeling rather than legacy exclusions.
- Alpha4beta2 partial agonism
- Titration
- Flexible quit date
- Renal dosing
- Safety monitoring
Partial stimulation reduces withdrawal without nicotine replacement.
Receptor occupancy reduces the rewarding effect of smoking.
Flexible starts and renal limits make the regimen patient specific.
Connect mechanism to the experience
Varenicline partially stimulates alpha4beta2 nicotinic receptors to reduce withdrawal while occupying the receptor and reducing nicotine reward. It is not nicotine replacement. Behavioral support remains part of the treatment.
Select a labeled start strategy
Treatment can begin one week before a fixed quit date, with quitting between days 8 and 35, or through a gradual reduction strategy for selected patients. Titration from 0.5 mg once daily reduces early adverse effects before the usual 1 mg twice-daily target.
Adjust for kidney function
Mild to moderate renal impairment does not require routine adjustment. Severe impairment begins at 0.5 mg once daily and can increase only to 0.5 mg twice daily. For hemodialysis, the labeled maximum is 0.5 mg once daily if tolerated.
Counsel from the current label
Nausea, abnormal dreams, insomnia, mood or behavior changes, seizures, alcohol effects, cardiovascular symptoms, and rare serious hypersensitivity or skin reactions require review. A seizure history is a precaution requiring judgment, not a universal labeled contraindication.
Quick check
Lesson
Reduce Withdrawal Without Adding Nicotine
Bupropion SR can reduce craving and withdrawal, but formulation, dose spacing, seizure risk, duplicate therapy, blood pressure, and psychiatric monitoring are nonnegotiable parts of prescribing.
- Norepinephrine and dopamine
- SR regimen
- Contraindications
- Blood pressure
- Dose integrity
Steady exposure develops during the first treatment week.
SR integrity and timing reduce avoidable peak exposure.
Contraindications, duplicate therapy, and monitoring define safety.
Use the labeled regimen
Begin 150 mg once daily for three days, then 150 mg twice daily at least eight hours apart when appropriate. Start before the planned quit date so exposure builds during the first week. The usual course is 7 to 12 weeks, with individualized longer treatment.
Protect modified release
Swallow SR tablets whole. Do not crush, divide, or chew. If a dose is missed, skip it rather than doubling. Separate doses by at least eight hours and avoid dosing too close to bedtime when insomnia occurs.
Screen formal exclusions
Do not use bupropion with a seizure disorder, current or prior bulimia or anorexia nervosa, abrupt discontinuation of alcohol, benzodiazepines, barbiturates, or antiseizure medicines, prohibited MAOI timing, duplicate bupropion, or hypersensitivity. Review other factors that lower seizure threshold.
Monitor the full patient
Assess blood pressure, sleep, agitation, mood or behavior change, alcohol use, kidney and liver function, and interacting medicines. Blood-pressure monitoring is especially important when bupropion is combined with a nicotine patch.
Quick check
Lesson
Change the Evidence Frame When the Patient Changes
The standard adult algorithm cannot simply be copied into pregnancy, adolescence, psychiatric illness, or complex comorbidity. Current guidance supports treatment while preserving each population's evidence limits.
- Pregnancy
- Adolescents
- Psychiatric illness
- Cardiovascular disease
- Shared decisions
Medication requires an individualized uncertainty discussion.
Counseling anchors care and selected medicines may be considered.
Psychiatric and cardiovascular conditions require monitoring, not stigma.
Protect pregnancy evidence boundaries
USPSTF recommends behavioral interventions during pregnancy and finds the evidence insufficient to determine the balance of medication benefits and harms. If counseling is insufficient and medication is considered, use an individualized risk discussion rather than retired pregnancy letters or a routine adult algorithm.
Use current adolescent guidance
The 2025 ATS guideline strongly recommends counseling, conditionally suggests technology-based support, varenicline, and bupropion for ages 10 through 18, and reached no consensus on NRT. These are not mandates. Development, confidentiality, family context, product type, and very low-certainty medication evidence matter.
Treat psychiatric illness without stigma
Psychiatric illness does not automatically exclude varenicline, NRT, or bupropion, though bupropion-specific contraindications still apply. Establish baseline symptoms, monitor behavior and mood, coordinate care, and separate withdrawal from medication effects and illness change.
Compare treatment with continued exposure
Stable cardiovascular disease is not a blanket reason to withhold cessation medication. Recent unstable events require closer coordination and product-specific judgment. The comparison includes the substantial risk of continued smoking, not medication risk in isolation.
Quick check
Lesson
Protect the Quit After the Quit Date
Medication initiation is the beginning of care. Smoke-related interactions, early withdrawal, lapses, dual use, treatment duration, and changing life conditions require planned follow-up.
- CYP1A2
- Early follow-up
- Vaping boundary
- Dual use
- Relapse prevention
Review withdrawal, adverse effects, adherence, and lapses.
CYP1A2 substrate exposure can rise when combustion stops.
Plan duration, high-risk situations, and rapid recovery.
Separate smoke from nicotine interactions
Polycyclic aromatic hydrocarbons in smoke induce CYP1A2. When smoking stops, concentrations of substrates such as clozapine, olanzapine, theophylline, and caffeine can rise within days. Nicotine replacement does not maintain smoke-related induction. Monitor and coordinate dose changes rather than applying an automatic percentage.
Follow the period of greatest change
Arrange contact near the quit date and again according to risk. Assess current product use, withdrawal, cravings, adherence, technique, adverse effects, blood pressure when relevant, mood, medication interactions, support, and the next high-risk situation.
Keep vaping claims accurate
No e-cigarette is FDA approved as a cessation aid. Some adults may reduce cigarette exposure through complete substitution, but dual use does not protect health and long-term effects remain uncertain. Prefer proven treatments and create a plan to end combustible use and later vaping.
Maintain treatment beyond abstinence
Review whether medication should continue, taper, or extend. Current varenicline labeling recommends an additional 12 weeks for successful quitters, and other therapies can also require individualized duration. Build a response plan for travel, alcohol, stress, social exposure, and a future lapse.
Quick check
Module test
Check the connections.
Each attempt draws 10 questions from the complete 160 question bank.
Each attempt draws a fresh set and rearranges the answer choices.
References
Current clinical foundation.
Lecture material was synthesized with the following contemporary guidance. Verify local policy and current guidance before applying clinical information.
- USPSTF. Tobacco Smoking Cessation in Adults, Including Pregnant Persons: Interventions.
- American Thoracic Society. Initiating Pharmacologic Treatment in Tobacco-Dependent Adults.
- American Thoracic Society. Treatment of Nicotine Use in Adolescents 10 to 18 Years of Age.
- CDC. How to Quit Smoking.
- CDC. Quit Smoking Medicines.
- CDC. How Quit Smoking Medicines Work.
- CDC. Vaping and Quitting.
- DailyMed. Varenicline Tablets Prescribing Information.
- DailyMed. Bupropion Hydrochloride Extended-Release Tablets SR Prescribing Information.
- DailyMed. Nicotrol Inhaler Prescribing Information.
- DailyMed. Nicotrol NS Prescribing Information.
- CDC. Smoking Cessation: A Report of the Surgeon General, Chapter 6.
- MHRA. Smoking and Smoking Cessation: Clinically Significant Interactions With Commonly Used Medicines.